The ACIP (ACIP) US Advisory Committee (ACIP) has decided to recommend the use of respiratory cell fusion virus (RSV) vaccines, including GSK’s auxiliary Arrexvy, to use it for adult population between 50 and 59 years old, with a high risk of serious diseases.
This group includes an individual with asthma, heart disease, diabetes and chronic obstructive pulmonary disease (COPD) and individuals who are treated with residential treatment.
Those with these conditions are more vulnerable to the serious consequences of RSV, which can lead to hospitalization, pneumonia and mortality.
This recommendation is based on voting on the use of RSV vaccines for people aged 60 to 74 and those aged 75 and over June 2024.
ACIP’s decision was influenced by the results of the III test that assessed the safety and immune response of RSV vaccines in groups 50-59 years old, especially for those with high risk of RSV low respiratory disease (RSV-LTD) due to certain medical conditions.
The vaccine was effective from a single capacity at age 60 or older.
Once approved, the committee’s recommendation will give medical service providers for the appropriate use of the vaccine and inform the scope of insurance coverage.
Tony Wood, the chief scientific officer of GSK, said: “We are satisfied with ACIP’s recommendations to expand the benefits of RSV immunity to adults over 50 to 59 years old, with an increase in the risk of serious consequences of this virus.
“RSV can have a big impact on people with fundamental medical conditions. We look forward to protecting more people through RSV vaccination.”
Auxiliary RSV vaccines combine protein F per stabilized recombinant RSV in the pre -fusion form (RSVPRREF3) with the company’s AS01.E Auxiliary agent.
Already, it has been approved to prevent RSV-LTDs of 60 years of age or older in 61 countries and regions, including the United States, Japan and Europe.
ABL BIO has previously signed a global license agreement with GSK to develop treatment for neurochromatic diseases.
